TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Endo International plc (NASDAQ: ENDP) Investor Securities Class Action Lawsuit 05/25/2016

  • If you purchased shares of Endo International plc (NASDAQ: ENDP), you may have certain options. Please contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Case Dismissed
Company
Endo International plc
Security
NASDAQ: ENDP

Case Name
Endo Shareholder Class Action Lawsuit 05/25/2016
Type of Lawsuit
Shareholder Class Action
Court of Filing
U.S. District Court for the Southern District of New York

Class Period Begin
Class Period End
Deadline To File for Lead
You must register or login to receive notifications.

Click here to subscribe to Endo International plc.
Summary

January 16, 2018 - The court granted defendants' motion to dismiss the case.

December 14, 2016 - A motion to dismiss the third amended complaint was filed.

November 16, 2016 - A third amended complaint was filed.

October 26, 2016 - A motion to dismiss the amended complaint was filed.

October 5, 2016 - An amended complaint was filed.

May 25, 2016 - An investor in shares of Endo International plc (NASDAQ: ENDP) filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Endo International plc in connection with certain allegedly false and misleading statements made between March 2, 2015 and May 6, 2016.

According to the complaint the plaintiff alleges on behalf of purchasers of Endo International plc (NASDAQ: ENDP) common shares between March 2, 2015 and May 6, 2016, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that between March 2, 2015 and May 6, 2016 the defendants made certain allegedly false and/or misleading statements and/or allegedly failed to disclose that Endo Pharmaceuticals’ arrangements with pharmacy benefit managers with respect to the migraine therapy Frova included questionable incentives intended to increase sales revenues, that consequently, Endo’s revenues and revenue projections relied in part on unsustainable arrangements, and that as a result of the foregoing, defendants’ statements about Endo’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On May 5, 2016, Endo International plc filed a Report with the SEC and issued a press release announcing the Company’s financial and operating results for the quarter ended March 31, 2016 (the “Q1 2015 Earnings Release”). In the Q1 2015 Earnings Release, Endo International plc reported a loss of $0.40 per diluted share, down from earnings of $0.11 per share in the first quarter of 2015. Additionally, Endo International plc significantly cut its 2016 guidance, announcing targeted revenue in the range of $3.87 billion and $4.03 billion, down from the range of $4.32 billion to $4.52 billion that the Company had reaffirmed in March, less than two months earlier.

Concurrently, Endo International plc announced changes to its board and management structure, including the resignation of Brian Lortie, President of the Company’s U.S. Branded Pharmaceuticals segment, pending selection of his replacement.

Shares of Endo International plc - Ordinary Shares (NASDAQ: ENDP) declined from as high as $94.46 per share in April 10, 2015 to as low as $12.56 per share on May 12, 2016.